HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now

Abstract Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. Thes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ilana Schlam, Sandra M. Swain
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5bfaa35b932a447fac6aa414a235208c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5bfaa35b932a447fac6aa414a235208c
record_format	dspace
spelling	oai:doaj.org-article:5bfaa35b932a447fac6aa414a235208c2021-12-02T17:18:05ZHER2-positive breast cancer and tyrosine kinase inhibitors: the time is now10.1038/s41523-021-00265-12374-4677https://doaj.org/article/5bfaa35b932a447fac6aa414a235208c2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00265-1https://doaj.org/toc/2374-4677Abstract Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. These drugs target HER2 and other receptors of the epidermal growth factor receptor family, therefore each has unique efficacy and adverse event profile. HER2-directed TKIs have been studied in the early stage and advanced settings and have shown promising responses. There is increasing interest in utilizing these drugs in combination with chemotherapy and /or other HER2-directed agents in patients with central nervous system involvement, TKIs have shown to be effective in this setting for which treatment options have been previously limited and the prognosis remains poor. The aim of this review is to summarize currently approved TKIs for HER2+ breast, key clinical trials, and their use in current clinical practice.Ilana SchlamSandra M. SwainNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ilana Schlam Sandra M. Swain HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
description	Abstract Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. These drugs target HER2 and other receptors of the epidermal growth factor receptor family, therefore each has unique efficacy and adverse event profile. HER2-directed TKIs have been studied in the early stage and advanced settings and have shown promising responses. There is increasing interest in utilizing these drugs in combination with chemotherapy and /or other HER2-directed agents in patients with central nervous system involvement, TKIs have shown to be effective in this setting for which treatment options have been previously limited and the prognosis remains poor. The aim of this review is to summarize currently approved TKIs for HER2+ breast, key clinical trials, and their use in current clinical practice.
format	article
author	Ilana Schlam Sandra M. Swain
author_facet	Ilana Schlam Sandra M. Swain
author_sort	Ilana Schlam
title	HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
title_short	HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
title_full	HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
title_fullStr	HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
title_full_unstemmed	HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
title_sort	her2-positive breast cancer and tyrosine kinase inhibitors: the time is now
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5bfaa35b932a447fac6aa414a235208c
work_keys_str_mv	AT ilanaschlam her2positivebreastcancerandtyrosinekinaseinhibitorsthetimeisnow AT sandramswain her2positivebreastcancerandtyrosinekinaseinhibitorsthetimeisnow
_version_	1718381146653327360

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now

Ejemplares similares